FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3139059474> ?p ?o ?g. }

• W3139059474 endingPage "659" @default.
• W3139059474 startingPage "653" @default.
• W3139059474 abstract "Clinical trials demonstrated that PARPi (poly [adenosine diphosphate-ribose]-ADP polymerase inhibitor) therapy is effective in solid tumors. However, long term effects such as therapy-related myelodysplastic syndrome or acute myeloid leukemia (MDS/AML) are poorly described. We sought to quantify whether PARPi therapy is associated with the development of MDS/AML.Medline, Embase, and Cochrane databases were searched (inception to January 6, 2020) and phase 2 and 3 clinical trials that randomized patients with solid tumors to a PARPi or control therapy were included. The PRISMA guidelines were used to extract data independently by multiple authors. We extracted person-time and number of cases of MDS/AML in the PARPi and control arms of each study and pooled results with a random-effects Poisson regression model. The pooled incidence rate ratio (IRR) for MDS/AML among patients randomized to PARPi therapy was compared to those randomized to a control.We identified 14 studies that included 5739 patients. Accounting for intra-study clustering, the risk of MDS/AML was similar in patients who were randomly assigned to receive PARPi compared to controls (IRR 1.32, 95% confidence interval [CI] 0.78-2.26). In the front-line setting, PARPi therapy was associated with developing MDS/AML (IRR 5.43, 95% CI 1.51-19.60). Among patients treated for recurrence, however, the risk of MDS/AML appeared to be similar among patients randomized to PARPi or control treatment. Among studies that included only patients with a BRCA mutation, the risk of MDS/AML was similar in both treatment groups (IRR 0.83, 95% CI 0.45-1.53), but PARPi therapy was associated with MDS/AML in studies with an unrestricted population (IRR 2.43, 95% CI 1.17-5.06).The pooled overall effect was not statistically significant. However, treatment with PARPi was associated with a statistically significant increase in the incidence of MDS/AML among patients receiving front-line cancer therapy and those with limited prior exposure to chemotherapy." @default.
• W3139059474 created "2021-03-29" @default.
• W3139059474 creator A5002038978 @default.
• W3139059474 creator A5009234043 @default.
• W3139059474 creator A5027028437 @default.
• W3139059474 creator A5034284419 @default.
• W3139059474 creator A5053431449 @default.
• W3139059474 creator A5058249824 @default.
• W3139059474 creator A5059228694 @default.
• W3139059474 creator A5066429339 @default.
• W3139059474 creator A5078692182 @default.
• W3139059474 creator A5083352688 @default.
• W3139059474 date "2021-06-01" @default.
• W3139059474 modified "2023-10-18" @default.
• W3139059474 title "Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials" @default.
• W3139059474 cites W1905741998 @default.
• W3139059474 cites W1964462241 @default.
• W3139059474 cites W1979423827 @default.
• W3139059474 cites W1989782940 @default.
• W3139059474 cites W2030566540 @default.
• W3139059474 cites W2033816200 @default.
• W3139059474 cites W2074950349 @default.
• W3139059474 cites W2111429259 @default.
• W3139059474 cites W2135409663 @default.
• W3139059474 cites W2141075397 @default.
• W3139059474 cites W2147071985 @default.
• W3139059474 cites W2156098321 @default.
• W3139059474 cites W2160466424 @default.
• W3139059474 cites W2168615560 @default.
• W3139059474 cites W2192186062 @default.
• W3139059474 cites W2194177867 @default.
• W3139059474 cites W246286872 @default.
• W3139059474 cites W2474664935 @default.
• W3139059474 cites W2512013138 @default.
• W3139059474 cites W2519148856 @default.
• W3139059474 cites W2523463218 @default.
• W3139059474 cites W2528228811 @default.
• W3139059474 cites W2531125083 @default.
• W3139059474 cites W2585794098 @default.
• W3139059474 cites W2588681363 @default.
• W3139059474 cites W2621271973 @default.
• W3139059474 cites W2737389832 @default.
• W3139059474 cites W2742790872 @default.
• W3139059474 cites W2749642104 @default.
• W3139059474 cites W2754327139 @default.
• W3139059474 cites W2763602017 @default.
• W3139059474 cites W2788106879 @default.
• W3139059474 cites W2808238124 @default.
• W3139059474 cites W2886477543 @default.
• W3139059474 cites W2893157368 @default.
• W3139059474 cites W2896628407 @default.
• W3139059474 cites W2897430921 @default.
• W3139059474 cites W2906323921 @default.
• W3139059474 cites W2913584903 @default.
• W3139059474 cites W2947826965 @default.
• W3139059474 cites W2948947061 @default.
• W3139059474 cites W2970684805 @default.
• W3139059474 cites W2975141952 @default.
• W3139059474 cites W2976139792 @default.
• W3139059474 cites W2994977341 @default.
• W3139059474 cites W3006801800 @default.
• W3139059474 cites W3030566019 @default.
• W3139059474 cites W3033972331 @default.
• W3139059474 cites W3048967410 @default.
• W3139059474 cites W3089254712 @default.
• W3139059474 cites W3113077828 @default.
• W3139059474 cites W4294215472 @default.
• W3139059474 doi "https://doi.org/10.1016/j.ygyno.2021.03.011" @default.
• W3139059474 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8164998" @default.
• W3139059474 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33736856" @default.
• W3139059474 hasPublicationYear "2021" @default.
• W3139059474 type Work @default.
• W3139059474 sameAs 3139059474 @default.
• W3139059474 citedByCount "21" @default.
• W3139059474 countsByYear W31390594742021 @default.
• W3139059474 countsByYear W31390594742022 @default.
• W3139059474 countsByYear W31390594742023 @default.
• W3139059474 crossrefType "journal-article" @default.
• W3139059474 hasAuthorship W3139059474A5002038978 @default.
• W3139059474 hasAuthorship W3139059474A5009234043 @default.
• W3139059474 hasAuthorship W3139059474A5027028437 @default.
• W3139059474 hasAuthorship W3139059474A5034284419 @default.
• W3139059474 hasAuthorship W3139059474A5053431449 @default.
• W3139059474 hasAuthorship W3139059474A5058249824 @default.
• W3139059474 hasAuthorship W3139059474A5059228694 @default.
• W3139059474 hasAuthorship W3139059474A5066429339 @default.
• W3139059474 hasAuthorship W3139059474A5078692182 @default.
• W3139059474 hasAuthorship W3139059474A5083352688 @default.
• W3139059474 hasBestOaLocation W31390594742 @default.
• W3139059474 hasConcept C120665830 @default.
• W3139059474 hasConcept C121332964 @default.
• W3139059474 hasConcept C126322002 @default.
• W3139059474 hasConcept C143998085 @default.
• W3139059474 hasConcept C168563851 @default.
• W3139059474 hasConcept C2778729363 @default.
• W3139059474 hasConcept C2780007613 @default.
• W3139059474 hasConcept C2780817109 @default.
• W3139059474 hasConcept C535046627 @default.

• next